Oppenheimer & Co. Inc. lifted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 121.4% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,964 shares of the company’s stock after purchasing an additional 3,270 shares during the period. Oppenheimer & Co. Inc.’s holdings in Neurocrine Biosciences were worth $537,000 at the end of the most recent reporting period.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
Several other hedge funds have also made changes to their positions in NBIX. Evolution Wealth Advisors LLC acquired a new position in shares of Neurocrine Biosciences in the 2nd quarter valued at approximately $40,000. Capital Investment Advisory Services LLC purchased a new stake in shares of Neurocrine Biosciences in the second quarter valued at $43,000. NEXT Financial Group Inc boosted its position in shares of Neurocrine Biosciences by 89.8% in the second quarter. NEXT Financial Group Inc now owns 560 shares of the company’s stock worth $47,000 after buying an additional 265 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of Neurocrine Biosciences by 70.5% during the second quarter. Tower Research Capital LLC TRC now owns 595 shares of the company’s stock valued at $51,000 after buying an additional 246 shares in the last quarter. Finally, Flagship Harbor Advisors LLC purchased a new position in shares of Neurocrine Biosciences during the third quarter valued at $67,000. Hedge funds and other institutional investors own 97.13% of the company’s stock.
Neurocrine Biosciences stock opened at $116.76 on Tuesday. The company has a market capitalization of $10.74 billion, a P/E ratio of 530.73, a P/E/G ratio of 5.90 and a beta of 1.24. Neurocrine Biosciences, Inc. has a 1-year low of $64.72 and a 1-year high of $118.42. The firm’s fifty day simple moving average is $105.65 and its 200-day simple moving average is $93.62. The company has a current ratio of 7.08, a quick ratio of 6.99 and a debt-to-equity ratio of 0.83.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Monday, November 4th. The company reported $0.56 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.63 by ($0.07). The business had revenue of $222.09 million for the quarter, compared to analyst estimates of $211.31 million. Neurocrine Biosciences had a return on equity of 5.67% and a net margin of 3.12%. The company’s quarterly revenue was up 46.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.52 earnings per share. On average, equities research analysts predict that Neurocrine Biosciences, Inc. will post 0.82 earnings per share for the current year.
In other news, insider Dimitri E. Grigoriadis sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $115.98, for a total value of $579,900.00. Following the sale, the insider now directly owns 113,408 shares in the company, valued at approximately $13,153,059.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Malcolm Lloyd-Smith sold 9,956 shares of the stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $90.85, for a total transaction of $904,502.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 46,131 shares of company stock valued at $4,745,275. 4.30% of the stock is owned by company insiders.
Several equities research analysts recently issued reports on the company. ValuEngine downgraded Neurocrine Biosciences from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Royal Bank of Canada set a $118.00 target price on Neurocrine Biosciences and gave the company a “buy” rating in a report on Friday, September 6th. TheStreet raised shares of Neurocrine Biosciences from a “c+” rating to a “b” rating in a research report on Tuesday, November 19th. BidaskClub raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Friday, November 8th. Finally, Zacks Investment Research lowered shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $105.72.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
See Also: What are CEFs?